News & Articles

The Center for Clinical and Translational Sciences at UTHealth Houston has secured a $55.5 million grant from the National Center for Advancing Translational Sciences, an agency of the National Institutes of Health, extending its funding through 2031.

Bleeding is the most common cause of preventable death after injury. Researchers at UTHealth Houston are asking for community input on whether they should participate in a study that will compare two resuscitation treatments: whole blood versus traditional blood component therapy, and tranexamic acid versus no tranexamic acid. The goal is to compare which strategies can improve survival for children who have been seriously injured and are in danger of bleeding to death.

Men with dementia who were taking beta-blockers showed a slight decrease in the rate of bone loss compared with men who were not, according to a small observational study led by researchers at UTHealth Houston.

Groundbreaking research initiatives to advance the treatment of traumatic injuries at UTHealth Houston have been funded with $3.4 million in grants from the Trauma Research and Combat Casualty Collaborative (TRC4), an initiative of The University of Texas System. 

A significant link between the use of electronic cigarettes and earlier age of asthma onset in U.S. adults was reported by UTHealth Houston researchers today in the Journal of the American Medical Association (JAMA) Network Open.

For the first time in her 37 years, Andrea Price is eating any food she wants.

Delaying surgical inguinal hernia repair in preterm infants until after discharge from the neonatal intensive care unit (NICU) appears to reduce the likelihood of serious adverse events, according to researchers at UTHealth Houston. 

Safety concerns for patients undergoing anesthesia who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are medications approved for diabetes and weight management, were revealed in a UTHealth Houston study published today in JAMA Surgery.

Semaglutide is a safe, effective therapy for a common fatty liver disease in people with HIV, according to the results of a clinical trial presented by UTHealth Houston.